株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インフルエンザワクチンの世界市場 (2017-2027年):三価/四価ワクチンの予測・パイプライン分析

Global Influenza Vaccines - World Industry Market Outlook 2017-2027: Forecasts for Trivalent Influenza Vaccines & Quadrivalent Influenza Vaccines, Analysis of Pipeline Developments For Fluzone/VaxiGrip, Seqirus, Fluarix/FluLaval, FluMist/Fluenz, FluBlok

発行 Visiongain Ltd 商品コード 349913
出版日 ページ情報 英文 147 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=143.15円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
インフルエンザワクチンの世界市場 (2017-2027年):三価/四価ワクチンの予測・パイプライン分析 Global Influenza Vaccines - World Industry Market Outlook 2017-2027: Forecasts for Trivalent Influenza Vaccines & Quadrivalent Influenza Vaccines, Analysis of Pipeline Developments For Fluzone/VaxiGrip, Seqirus, Fluarix/FluLaval, FluMist/Fluenz, FluBlok
出版日: 2017年01月03日 ページ情報: 英文 147 Pages
概要

2017年における世界のインフルエンザワクチンの市場は、49億7000万ドルの収益規模を記録すると予測されています。

当レポートでは、世界のインフルエンザワクチンの市場を調査し、市場背景、市場成長を推進する産業動向、三価ワクチンから四価ワクチンへの移行動向、主なインフルエンザワクチンの分析・売上予測、主な先進国・新興国市場の動向分析および市場予測、R&Dパイプラインの動向、SWOT分析・STEP分析、将来の展望などをまとめています。

第1章 調査概要

第2章 イントロダクション:世界のインフルエンザワクチン市場

  • インフルエンザによる死亡者数
  • インフルエンザの大きな社会的・経済的負担
  • インフルエンザウイルスの年々の変異と前年のワクチンの無効化
  • 流行と世界的流行の発生
  • インフルエンザワクチン市場に影響力を持つ主な企業・組織

第3章 インフルエンザワクチン市場の展望・予測

  • 市場実績
  • 収益予測
  • 産業動向・予測
    • 需要を推進する動向
    • 売上に影響を及ぼす供給効率
    • 資金動向
    • 労働力の保護

第4章 QIVワクチン:近い将来におけるTIVワクチンからのシフト

  • 三価不活化インフルエンザワクチン (TIV)
  • 四価ワクチン (QIV)
  • インフルエンザワクチン:三価・四価タイプ

第5章 主なインフルエンザワクチンの収益予測

  • Sanofi Pasteur:製品ポートフォリオ・売上予測・ディスカッション
  • Seqirus:製品ポートフォリオ・売上予測・ディスカッション
  • GSK:製品ポートフォリオ・売上予測・ディスカッション
  • AstraZeneca:製品ポートフォリオ・売上予測・ディスカッション
  • Protein Sciences Company:製品ポートフォリオ・売上予測・ディスカッション
  • その他:製品ポートフォリオ・売上予測・ディスカッション
  • Sanofi Pasteur:世界市場での優位的立場

第6章 主要先進国市場の予測

  • 主要国のインフルエンザワクチン市場の実績・予測
  • 米国
    • 市場実績
    • 市場予測
    • 市場動向
  • 日本
    • 市場実績
    • 市場予測
    • 市場動向
  • 英国
    • 市場実績
    • 市場予測
    • 市場動向
  • ドイツ
    • 市場実績
    • 市場予測
    • 市場動向
  • フランス
    • 市場実績
    • 市場予測
    • 市場動向
  • イタリア
    • 市場実績
    • 市場予測
    • 市場動向
  • スペイン

第7章 主要新興国市場の予測

  • 主要国のインフルエンザワクチン市場の実績・予測
  • 中国
    • 市場実績
    • 市場予測
    • 市場動向
  • インド
    • 市場実績
    • 市場予測
    • 市場動向
  • ブラジル
    • 市場実績
    • 市場予測
    • 市場動向
  • ロシア
    • 市場実績
    • 市場予測
    • 市場動向

第8章 R&Dパイプライン

  • 開発中の季節性インフルエンザワクチン
    • Sanofi Pasteur
    • Seqirus
    • 武田薬品工業
    • 田辺三菱製薬
  • 開発中の万能インフルエンザワクチン

第9章 定性分析

  • SWOT分析
  • STEP分析

第10章 総論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0160

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $4.97 billion in 2017.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain's new study tells you and tells you NOW.

In this brand new 147 page report you find 64 in-depth tables, charts and graphs - all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Visiongain's new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:

  • Trivalent Influenza Vaccines (TIV)
  • Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share

  • Sanofi Pasteur
  • GSK
  • Seqirus
  • AstraZeneca
  • Protein Science Corporation.
  • Others

From 2017, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations' potentials.

Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:

  • Seasonal Influenza vaccines in development
  • Universal Influenza vaccines in development

The report includes forecasts and analysis of pipeline developments for the following specific vaccines

  • Fluzone / VaxiGrip
  • Seqirus
  • Fluarix / FluLaval
  • FluMist / Fluenz
  • FluBlok
  • Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2027 for 11 countries:

  • United States
  • Japan
  • The EU 5 - Germany, France, United Kingdom, Italy and Spain.
  • Brazil, Russia, India and China.

image1

Who should read this report?

  • Anyone within the influenza vaccines value chain.
  • Pharmaceutical companies
  • Vaccine manufacturers
  • Healthcare biotech companies
  • Generics and biosimilar producers
  • Drug delivery companies and other technology providers
  • Contract/clinical research organisations (CROs)
  • Pharma contract manufacturers,
  • Pharma/healthcare wholesale and distribution companies
  • Medical device companies
  • Healthcare diagnostics companies
  • R&D specialists
  • Business development managers
  • Marketing managers
  • Technologists
  • Suppliers
  • Investors
  • Banks
  • Government agencies
  • Contractors

Visiongain's study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Influenza Vaccine Market Overview
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to the World Influenza Vaccine Market

  • 2.1 The Influenza Virus Kills over 500,000 People Every Year
  • 2.2 Influenza has a Huge Social and Economic Burden on all Societies
  • 2.3 The Influenza Virus Mutates Annually Rendering the Previous Year's Vaccines Ineffective
    • 2.3.1 All Current Influenza Vaccines are either Trivalent (TIV) or Quadrivalent (QIV)
    • 2.3.2 The Antigenic Drift Mutation Causes Epidemics
    • 2.3.3 The Antigenic Shift Mutation Causes Pandemics
  • 2.4 An Epidemic or a Pandemic Outbreak?
    • 2.4.1 Seasonal Influenza Epidemic (Local)
    • 2.4.2 Pandemic Influenza (Worldwide): 'A' Subtype
    • 2.4.3 Flu Vaccine Effectiveness
  • 2.5 Key Influencers of the Influenza Vaccine Market
    • 2.5.1 Governments and International Organisations
      • 2.5.1.1 Every Year the World Health Organisation Identifies the Most Likely Strain of the Influenza Virus
      • 2.5.1.2 The Governmental Stance of the Importance of Influenza Directly Drives the Market
      • 2.5.1.3 The WHO's "Influenza Vaccine Production Transfer Project" Affects Big Pharma's Vaccine Sales
    • 2.5.2 Leading Manufacturers
      • 2.5.2.1 Sanofi Pasteur is the Market Leader
      • 2.5.2.2 CSL Has Bought Novartis's Flu Vaccine Business Forming a New Infuenza Vaccine Company Seqirus
      • 2.5.2.3 GSK is Now Third Placed in the Market
      • 2.5.2.4 AstraZeneca's Flumist Product is in Trouble

3. Influenza Vaccine World Market Outlook, 2017-2027

  • 3.1 The World Influenza Market Performance, 2015
    • 3.1.1 Growing Elderly Population
    • 3.1.2 Paediatric Influenza Vaccines - High Demand Markets
    • 3.1.3 Emerging Markets
  • 3.2 The World Influenza Market Revenue Forecast for 2016-2027
  • 3.3 The World Influenza Market: Industry Trends, 2017-2027
    • 3.3.1 Demand Driven Trends
    • 3.3.2 Supply Efficiency Affects Sales
    • 3.3.3 Funding Trends
    • 3.3.4 Protecting the Workforce of an Economy

4. TIV Vaccines will be Replaced by QIV Vaccines in the Near Future

  • 4.1 Trivalent Influenza Vaccines (TIV)
  • 4.2 Quadrivalent Vaccines (QIV)
  • 4.3 Influenza Vaccines by TIV and QIV Type

5. Leading Influenza Vaccines: Revenue Predictions, 2017-2027

  • 5.1 Sanofi Pasteur Influenza Vaccine Portfolio - Sales Forecasting and Discussion 2016-2027
  • 5.2 Seqirus Vaccine Portfolio - Sales Forecasting and Discussion 2016-2027
  • 5.3 GSK Influenza Vaccine Portfolio - Sales Forecasting and Discussion 2016-2027
  • 5.4 AstraZeneca Influenza Vaccine - Sales Forecasting and Discussion 2016-2027
  • 5.5 Protein Sciences Company Influenza Vaccine - Sales Forecasting and Discussion 2016-2027
  • 5.6 Other Vaccines: Sales Forecasting and Discussion 2016-2027
  • 5.7 Sanofi Pasteur Dominates the World Influenza Vaccines Market

6. Influenza Vaccines in Leading Developed Markets, 2017-2027

  • 6.1 Influenza Vaccines: Leading Markets, 2015, 2021, 2027
    • 6.1.1 Influenza Vaccine: Leading Developed Markets
  • 6.2 The US Vaccine Market: 2017-2027
    • 6.2.1 The US Vaccine Market: 2016
    • 6.2.2 The US Vaccine Market Forecast: 2016-2027
    • 6.2.3 Obama Healthcare Reform - the Benefits for Vaccine Sales
    • 6.2.4 In the US Influenza Vaccines Come Equally from Manufacturers and Distributors
  • 6.3 The Japanese Influenza Vaccine Market 2016-2027
    • 6.3.1 The Japanese Vaccine Market 2016
    • 6.3.2 The Japanese Vaccine Market Forecast 2016-2027
    • 6.3.3 Filing the Vaccine Gap
    • 6.3.4 Kaketsuken Loses Control of the Japanese Vaccine Market
  • 6.4 The United Kingdom Influenza Vaccine Market 2017-2027
    • 6.4.1 The UK Vaccine Market, 2016
    • 6.4.2 The UK Vaccine Market, 2016-2027
    • 6.4.3 Sanofi Pasteur's QIV Vaccine is Authorized for use in the UK
  • 6.5 The German Influenza Vaccine Market: 2017-2027
    • 6.5.1 The German Vaccine Market, 2016
    • 6.5.2 The German Vaccine Market: Forecast 2016-2027
  • 6.6 The French Influenza Vaccine Market 2017-2027
    • 6.6.1 The French Vaccine Market, 2016
    • 6.6.2 The French Vaccine Market: Forecast 2016-2027
    • 6.6.3 French Healthcare System - Events, Policies and Effects
    • 6.6.4 The French Population Have the Highest Doubt over Vaccine Safety in Europe
  • 6.7 The Italian Influenza Vaccine Market: 2017-2027
    • 6.7.1 The Italian Vaccine Market: 2016
    • 6.7.2 The Italian Vaccine Market Forecast: 2016-2027
    • 6.7.3 Uncertain Foundation - Challenges in Public Healthcare
  • 6.8 The Spanish Influenza Vaccine Market 2017-2027
    • 6.8.1 The Spanish Vaccine Market: 2016
    • 6.8.2 The Spanish Vaccine Market Forecast: 2016-2027
    • 6.8.3 District Rules - Economic Challenges

7. Influenza Vaccines in Leading Emerging Markets, 2017-2027

  • 7.1 Influenza Vaccines: Leading Markets, 2015, 2021, 2027
    • 7.1.1 Influenza Vaccine: Leading Emerging National Markets
  • 7.2 The Chinese Influenza Vaccine Market: 2017-2027
    • 7.2.1 The Chinese Influenza Vaccine Market: 2016
    • 7.2.2 The Chinese Influenza Vaccine Market Forecast: 2016-2027
    • 7.2.3 High National Demand for Influenza Vaccines
  • 7.3 The Indian Influenza Vaccine Market: 2017-2027
    • 7.3.1 The Indian Vaccine Market: 2016
    • 7.3.2 The Indian Influenza Vaccine Market Forecast: 2016-2027
    • 7.3.3 Complications of Influenza Vaccines - How Much Progress Possible?
  • 7.4 The Brazilian Influenza Vaccine Market: 2017-2027
    • 7.4.1 The Brazilian Vaccine Market: 2016
    • 7.4.2 The Brazilian Vaccine Market Forecast: 2016-2027
  • 7.5 The Russian Vaccine Market: 2017-2027
    • 7.5.1 The Russian Vaccine Market: 2016
    • 7.5.2 The Russian Vaccine Market Forecast: 2016-2027
    • 7.5.3 Power of the State

8. Research & Development Pipeline for Flu Vaccines

  • 8.1 Seasonal Influenza Vaccines in Development
    • 8.1.1 Sanofi Pasteur
      • 8.1.1.1 Fluzone QIV High Dose
      • 8.1.1.2 VaxiGrip QIV IM (6-35 months)
      • 8.1.1.3 VaxiGrip QIV IM (3 years +)
    • 8.1.2 Seqirus
      • 8.1.2.1 MF59 QIV and TIV Vaccines
    • 8.1.3 Takeda Pharmaceuticals
      • 8.1.3.1 Takeda has Ceased Development of it's TAK850 TIV Influenza Vaccine
    • 8.1.4 Mitsubishi Tanabe Pharma
      • 8.1.4.1 Plant Based Virus-Like- Particle Influenza Vaccine
  • 8.2 Universal Influenza Vaccines in Development

9. Qualitative Analysis of the World Influenza Vaccines Industry and Market, 2017- 2027

  • 9.1 SWOT Analysis of the World Influenza Vaccines Industry and Market, 2017
    • 9.1.1 Strengths
      • 9.1.1.1 Ageing Population
      • 9.1.1.2 Influenza Prevention is Crucial
      • 9.1.1.3 Sales Growth in Emerging National Markets
      • 9.1.1.4 Rising Awareness of the Disease
    • 9.1.2 Weaknesses
      • 9.1.2.1 Supply Chain Costs
      • 9.1.2.2 Time Pressure
      • 9.1.2.3 Barriers to Market Entry
    • 9.1.3 Opportunities
      • 9.1.3.1 Strong Research and Development Pipeline
      • 9.1.3.2 Vaccine Delivery - Innovations and Opportunities for Improvements
      • 9.1.3.3 Universal Flu Vaccine
      • 9.1.3.4 Adult Vaccines - High Need
    • 9.1.4 Threats
      • 9.1.4.1 Productivity Gap
  • 9.2 STEP Analysis of the World Influenza Vaccines Industry and Market, 2017
    • 9.2.1 Social Factors
      • 9.2.1.1 Creating a Healthier Society
      • 9.2.1.2 Public Fears of Side-Effects
    • 9.2.2 Technological Forces
      • 9.2.2.1 Advancements in Vaccine Technology
    • 9.2.3 Economic Factors
      • 9.2.3.1 Cost and Time Restraints
      • 9.2.3.2 Emerging Markets Create Demand
    • 9.2.4 Political Factors
      • 9.2.4.1 Influence of Governments

10. Conclusion

  • 10.1 Prevention of Influenza by Use of Flu Shots Rises in Importance
  • 10.2 Japan as a Rising Consumer in the World Influenza Vaccine Market
  • 10.3 Brazil and India Show Robust Growth
  • 10.4 Emergence of a Universal Flu Vaccine
  • 10.5 The US to Retain its Dominance
  • 10.6 Concluding Remarks

List of Tables

  • Table 1.1 Selected National Vaccines Markets: Revenues ($m) and Market Shares (%) by Leading Country, 2017, 2021 and 2027
  • Table 2.1 Influenza Vaccine Effectiveness (%) 2004/5-2015/6
  • Table 3.1 Overall World Influenza Vaccine Market: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015- 2027
  • Table 3.2 The World Market for Influenza Vaccines Divided into that for Pharmaceutical Companies and 'Others'; Revenue Forecast ($m) and Market Share (%), 2016- 2027
  • Table 4.1 Influenza Vaccines Divided into TIV and QIV Type, 2017
  • Table 5.1 Leading Influenza Vaccines: Revenues ($m), 2015
  • Table 5.2 Fluzone/VaxiGrip: Revenue ($m), 2013-2015
  • Table 5.3 Sanofi Pasteur (Fluzone/VaxiGrip); Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
  • Table 5.4 Seqirus Influenza Vaccines; Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
  • Table 5.5 Fluarix/FluLaval: Revenue ($m), 2013-2015
  • Table 5.6 Fluarix/FluLaval: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
  • Table 5.7 FluMist/Fluenz: Revenue ($m), 2013-2015
  • Table 5.8 FluMist/Fluenz: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
  • Table 5.9 FluBlok Revenue ($m), 2013-2014
  • Table 5.10 FluBlok: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
  • Table 5.11 Other Influenza Vaccines Forecast: ($m), Annual Growth ($m), CAGR (%), 2015-2027
  • Table 6.1 Influenza Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2015, 2021 and 2027
  • Table 6.2 The US Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2027
  • Table 6.3 The Japanese Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2016-2026
  • Table 6.4 The UK Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 6.5 The German Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 6.6 The French Human Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 6.7 The Italian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 6.8 The Spanish Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 7.1 Human Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2015, 2021 and 2027
  • Table 7.2 The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 7.3 The Indian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 7.4 The Brazilian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 7.5 The Russian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2016-2027
  • Table 8.1 Seasonal Influenza Vaccines in Development, 2016
  • Table 8.2 Universal Influenza Vaccines in Development, 2016

List of Figures

  • Figure 1.1 Influenza Vaccines Market Segmentation
  • Figure 3.1 Influenza Vaccine's Market Share of Global Vaccines Industry (%), 2015
  • Figure 3.2 Growth in the Uptake of Influenza Vaccines, 1990-2015
  • Figure 3.3 Influenza Vaccines: Segmentation by Age (%), 2015
  • Figure 3.4 Time of Last Influenza Vaccination by Age, 2016
  • Figure 3.5 Influenza Vaccines: Market Share by Geographical Region, 2015
  • Figure 3.6 The World Market for Influenza Vaccines Divided into Pharma Companies and 'Others', 2015- 2027
  • Figure 3.7 Influenza Market Share (%) by Pharma Companies and 'Others': 2015 and 2027
  • Figure 3.8 World Influenza Vaccines Market: Drivers and Restraints, 2017-2027
  • Figure 5.1 Fluzone/VaxiGrip: Revenue Forecast ($m), 2015-2027
  • Figure 5.2, Seqirus Influenza Vaccines; Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
  • Figure 5.3, GSK Influenza Vaccines; Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2027
  • Figure 5.4 FluMist/Fluenz: Revenue Forecast ($m), 2015-2027
  • Figure 5.5 FluBlok: Revenue Forecast ($m), 2015-2027
  • Figure 5.6 Other Influenza Vaccines: Revenue Forecast ($m), 2015-2027
  • Figure 5.7 Market Share (%) by Company of the Influenza Vaccine Market 2015 and 2027
  • Figure 5.8 Influenza Vaccines Market Revenues ($m) by Company, 2015-2027
  • Figure 6.1 Influenza Vaccine Market Share (%) by Country, 2015
  • Figure 6.2 Developed National Markets: Drivers and Restraints, 2016-2027
  • Figure 6.3 The US Influenza Vaccine Revenue Forecast ($m), 2016-2027
  • Figure 6.4 The Japanese Influenza Vaccine Revenue Forecast ($m), 2016-2027
  • Figure 6.5 The UK Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 6.6 The German Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 6.7 The French Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 6.8 The Italian Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 6.9 The Spanish Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 7.1 Emerging National Markets: Drivers and Restraints, 2017-2027
  • Figure 7.2 The Chinese Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 7.3 The Indian Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 7.4 The Brazilian Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 7.5 The Russian Influenza Vaccines Revenue Forecast ($m), 2016-2027
  • Figure 9.1 SWOT Analysis of the Influenza Vaccines Market, 2017
  • Figure 9.2 STEP Analysis of the Influenza Vaccines Market, 2017

Companies Listed

  • Advisory Committee for Immunization Practices
  • Astellas Pharmaceuticals
  • AstraZeneca
  • Bharat Immunologicals and Biologicals Corporation Limited
  • Binnopharm
  • bioCSL
  • BioManguinhos/Oswaldo Cruz Foundation
  • BiondVax
  • BiondVax
  • Bionor
  • Brazilian Ministry of Health
  • Butantan Institute
  • Center for Biologics Evaluation and Research
  • Centre for Disease Control and Prevention
  • China National Biotech Group
  • China's National Regulatory Authority
  • Chinese Food and Drug Administration
  • CSL
  • CureVac
  • Daiichi Sankyo
  • Dynavax
  • Flanders Institute
  • Food and Drug Administration
  • FORT
  • Fresenius Pharmaceuticals
  • Gamma Vaccines
  • Gavi Alliance
  • Glaxo Smith Klein
  • GlaxoWellcome
  • Global Influenza Programme
  • Grippol
  • Health Service Bureau, Japan
  • Immune Targeting Systems
  • Indian Association of Paediatrics
  • Janssen Pharmaceuticals
  • Jenner Institute, University of oxford
  • Johnson & Johnson
  • Krka Pharmaceuticals
  • Medicago
  • Medicare
  • MedImmune
  • Merck
  • MSD Pharmaceuticals
  • National Health Service, UK
  • Novartis
  • Organisation for Economic Co-operation and Development
  • Panacea Biotech
  • Partnership for Influenza Vaccine Introduction
  • Petrovax
  • Pfizer
  • Protein Science Corporation
  • Sanofi Pasteur
  • Servizio Sanitario Nationale
  • Shionogi Pharmaceuticals
  • Sistema Unico de Saude
  • SmithKline Beecham
  • Takeda Pharmaceuticals
  • Terumo Pharmaceuticals
  • The Ministry of Health, Labour and Welfare, Japan
  • The Scripps Research Institute
  • Ultriks
  • US Department of Health and Human Services
  • VaxInnate
  • WHO Strategic Advisory Group of Experts
  • World Health Organization
Back to Top